Zobrazeno 1 - 10
of 46
pro vyhledávání: '"A. U. Dignass"'
Autor:
Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis
Publikováno v:
Intestinal Research, Vol 21, Iss 1, Pp 161-167 (2023)
Externí odkaz:
https://doaj.org/article/45e18b6b5d02455eb3a2bcf5242f9cab
Autor:
Fernando Magro, Jakob Begun, Edouard Louis, Simon PL Travis, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Axel U Dignass, Juan Ricardo Márquez, Matthew J Freddi
Publikováno v:
BMJ Open Gastroenterology, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/1a9b8eff0f044c5cb9f5ed163c5fcf85
Publikováno v:
Der Internist. 63:155-164
Autor:
Gert Van Assche, Axel U. Dignass, Britta Siegmund, William J. Sandborn, Laurent Peyrin-Biroulet, James O. Lindsay, Iris Dotan
Publikováno v:
European Medical Journal Gastroenterology, Vol 4, Iss 1, Pp 40-49 (2015)
Despite major advances in the inflammatory bowel disease (IBD) treatment landscape, the management of ulcerative colitis (UC) and Crohn’s disease (CD) continues to pose challenges. There is significant scope to optimise treatment of IBD, and conven
Externí odkaz:
https://doaj.org/article/9897d92318654ba5b09492bfd373296a
Autor:
Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
Publikováno v:
Scandinavian Journal of Gastroenterology. 57:424-431
To understand current thinking and clinical decision-making in the treatment and management of patients with mild-to-moderate ulcerative colitis (UC). This multinational, survey-based study was conducted in 2021. Two meetings were held, involving 11
Autor:
Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis
Publikováno v:
Intestinal research.
Publikováno v:
Der InternistLiteratur. 63(2)
In addition to conventional anti-inflammatory treatment for chronic inflammatory bowel disease (IBD), there has been an evolution of new treatment options over the past 20 years. Already approved biologics provide multiple treatment alternatives but
Publikováno v:
Journal of Crohn's and Colitis. 16:i418-i418
Background SB5, a biosimilar to reference adalimumab (ADL), received EU marketing authorisation in August, 2017, based on pre-clinical and clinical phase I and III studies that demonstrated bioequivalence and comparable efficacy, safety and immunogen
Autor:
Torsten, Kucharzik, Axel U, Dignass, Raja, Atreya, Bernd, Bokemeyer, Philip, Esters, Klaus, Herrlinger, Klaus, Kannengießer, Peter, Kienle, Jost, Langhorst, Andreas, Lügering, Stefan, Schreiber, Andreas, Stallmach, Jürgen, Stein, Andreas, Sturm, Niels, Teich, Britta, Siegmund, Jennifer, Zemke
Publikováno v:
Zeitschrift fur Gastroenterologie. 57(11)
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e29756 (2012)
INTRODUCTION: Despite the excellent anti-inflammatory and immunosuppressive action of glucocorticoids (GCs), their use for the treatment of inflammatory bowel disease (IBD) still carries significant risks in terms of frequently occurring severe side
Externí odkaz:
https://doaj.org/article/8302a36ba7df4ff29c0c404d1f1756e3